Supplementary Material for: Clinical Features and Prognostic Factors of Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multicenter Study from the Turkish Oncology Group Kidney Cancer Consortium

<b><i>Introduction:</i></b> We aimed to evaluate clinical features, prognostic factors, and treatment preferences in patients with non-clear cell renal cell carcinoma (nccRCC). <b><i>Methods:</i></b> Patients with metastatic nccRCC were selected from the Turkish Oncology Group Kidney Cancer Consortium (TKCC) database. Clinical features, prognostic factors, and overall survival (OS) outcomes were investigated. <b><i>Results:</i></b> A total of 118 patients diagnosed with nccRCC were included in this study. The median age at diagnosis was 62 years (interquartile range: 56–69). Papillary (57.6%) and chromophobe tumors (12.7%) are common histologic subtypes. Sarcomatoid differentiation was present in 19.5% of all patients. When the patients were categorized according to the International Metastatic RCC Database Consortium (IMDC) risk scores, 66.9% of the patients were found to be in the intermediate or poor risk group. Approximately half of the patients (55.9%) received interferon in the first line. At the median follow-up of 53.2 months (95% confidence interval [CI]: 34.7–71.8), the median OS was 19.3 months (95% CI: 14.1–24.5). In multivariate analysis, lung metastasis (hazard ratio [HR]:2.22, 95% CI: 1.23–3.99) and IMDC risk score (HR: 2.35, 95% CI: 1.01–5.44 for intermediate risk; HR: 8.86, 95% CI: 3.47–22.61 for poor risk) were found to be independent prognostic factors. <b><i>Conclusion:</i></b> In this study, survival outcomes are consistent with previous studies. The IMDC risk score and lung metastasis are the independent prognostic factors for OS. This is an area that needs research to better treat this group of patients and create new treatment options.

<b><i>引言：</i></b> 本研究旨在评估非透明细胞肾细胞癌（non-clear cell renal cell carcinoma, nccRCC）患者的临床特征、预后因素及治疗偏好。<b><i>方法：</i></b> 本研究从土耳其肿瘤学会肾癌联盟（Turkish Oncology Group Kidney Cancer Consortium, TKCC）数据库中筛选转移性非透明细胞肾细胞癌患者，对其临床特征、预后因素与总生存期（overall survival, OS）结局展开分析。<b><i>结果：</i></b> 本研究共纳入118例经病理确诊的非透明细胞肾细胞癌患者。患者确诊时中位年龄为62岁（四分位间距：56~69岁）。乳头状肾细胞癌（57.6%）与嫌色细胞癌（12.7%）为该研究人群中常见的组织学亚型。19.5%的患者存在肉瘤样分化。依据国际转移性肾癌数据库联盟（International Metastatic RCC Database Consortium, IMDC）风险评分进行分组后，66.9%的患者被归为中危或高危组。约半数患者（55.9%）接受干扰素作为一线治疗方案。中位随访时长为53.2个月（95%置信区间（confidence interval, CI）：34.7~71.8），中位总生存期为19.3个月（95%CI：14.1~24.5）。多因素分析结果显示，肺转移（风险比（hazard ratio, HR）：2.22，95%CI：1.23~3.99）与IMDC风险评分（中危组HR：2.35，95%CI：1.01~5.44；高危组HR：8.86，95%CI：3.47~22.61）为独立预后因素。<b><i>结论：</i></b> 本研究所得生存结局与既往相关研究结果一致。IMDC风险评分与肺转移为总生存期的独立预后因素。目前仍需开展更多相关研究，以优化该类患者的治疗方案并开发新型治疗选择。